NCT01740375终止3 期
A Randomized Phase III Trial on the Role of Esophagectomy in Complete Responders to Preoperative Chemoradiotherapy for Squamous Cell Carcinoma of Esophagus
适应症
干预措施
试验速览
- 阶段
- 3 期
- 状态
- 终止
- 入组人数
- 486
- 试验地点
- 2
- 主要终点
- 2-year disease-free survival (DFS) rate
研究概览
简要总结
To investigate the role of esophagectomy in complete responders to preoperative chemoradiotherapy for squamous cell carcinoma of esophagus, patients will be randomized to either observation or esophagectomy after concurrent chemoradiotherapy.
详细描述
After completion of concurrent chemoradiotherapy, patients will be reassed and visited to multidisciplinary clinic, then, randomized to either observation or esophagectomy.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 20 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologically proven squamous cell carcinoma of the intrathoracic esophagus
- •Surgically resectable (cT3, cT4a and/or disease with lymph node metastasis by AJCC 7th ed) esophageal cancer, as determined by Endoscopic Ultra Sound (EUS), chest CT and PET-CT
- •No prior treatment for the esophageal cancer
- •Age: 20-70 years
- •ECOG performance status 0, 1 or 2
- •Adequate hematological, renal, hepatic, pulmonary and cardiac functions defined as 6.1 Granulocytes > 1,500/microliter, Platelets > 75,000/microliter 6.2 Creatinine < 1.5 mg/dL (or CCr> 50 mg/mL), 6.3 Total bilirubin < 1.5 mg/dL 6.4 ALT and AST < 2.5 × upper normal limit 6.5 FEV1 >=1.5 L/min 6.6 Ejection fraction >= 45%
- •Non-pregnant, non-lactating female patients. Sexually active patients of childbearing potential must implement effective contraceptive practices during the study when treated with chemotherapy
- •Written, voluntary informed consent
排除标准
- •Subtypes other than squamous cell carcinoma
- •cT1N0M0, cT2N0M0 esophageal cancer or in situ carcinoma
- •Invasion of recurrent laryngeal, phrenic or sympathetic nerve
- •Invasion of the tracheobronchial tree or presence of tracheoesophageal fistula
- •Invasion of major vessels (vena cava, azygos vein and aorta) by the tumor
- •Malignant pleural effusion (documented by cytospin or cytology)
- •Cervical esophageal cancer
- •Para-aortic lymph node metastasis
- •Past or current history of malignancy other than entry diagnosis except for non-melanomatous skin cancer, curatively treated carcinoma in situ of the cervix, curatively treated early gastric cancer with endoscopic mucosal resection or a cured malignancy more than 5 years prior to enrollment
- •Previous chemotherapy or prior history of radiotherapy interfering with the planned radiotherapy as per protocol
- •Patients with a known history of HIV seropositivity or HCV (+). Patients with HBV (+) are eligible. However, primary prophylaxis using antiviral agents (i.e. lamivudine, etc) is recommended for HBV carrier to prevent HBV reactivation during whole treatment period.
- •Other serious illness or medical conditions A. Unstable cardiac disease (i.e. congestive heart failure, arrhythmia, symptomatic coronary artery disease) despite treatment, myocardial infarction within 6 months prior to study entry B. History of significant neurologic or psychiatric disorders including dementia or seizures C. Active uncontrolled infection (viral, bacterial or fungal infection) D. Other serious medical illnesses
- •New York heart Association Class III/IV and history of active angina. Documented myocardial infarction within the 6 months preceding registration. Patients with a history of significant ventricular arrhythmia requiring medication or congestive heart failure. History of 2nd or 3rd degree heart blocks.
- •Active infection or other serious underlying medical condition which would impair the ability of the patient to receive the planned treatment
- •Dementia or altered mental status that would prohibit the understanding and giving of informed consent
- •Uncontrolled diabetes mellitus: fasting glucose >150 mg/dL or patients requiring insulin therapy for glycemic control; fasting glucose >150 mg/dL or patients requiring insulin therapy for glycemic control;
研究组 & 干预措施
Arm B: observation:
No Intervention
No additional treatment after concurrent chemoradiotherapy. However, esophagectomy will be considered as a salvage treatment for local recurrence during observation.
Arm A: esophagectomy
Experimental
Esophagectomy will be performed preferentially within 8 weeks (maximum 12 weeks) after completion of concurrent chemoradiotherapy
干预措施: esophagectomy (Procedure)
结局指标
主要结局
2-year disease-free survival (DFS) rate
时间窗: 2 years from the enrollment of last patient
次要结局
- Overall survival (OS)(5 years from the enrollment of last patient)
- progression-free survival(5 years from the enrollment of last patient)
- failure pattern(5 years from the enrollment of last patient)
- Number of Participants with Adverse Events(up to 60 days after treatment)
- Comparison of clinical complete response (cCR) vs. pathologic complete response rate (pCR) in patients who underwent esophagectomy(5 years)
- Comparison of OS according to clinical response (CR vs PR vs SD/PD) after preoperative chemoradiotherapy among those who underwent preplanned esophagectomy;(5 years from the enrollment of the last patient)
- Comparison of OS according to metabolic response after induction chemotherapy(5 years from the enrollment of the last patient)
- Quality of life(5 years from the enrollment of the last patient)
- Comparison of PFS according to clinical response (CR vs PR vs SD/PD) after preoperative chemoradiotherapy among those who underwent preplanned esophagectomy;(5 years from the enrollment of the last patient)
- Comparison of TTF according to clinical response (CR vs PR vs SD/PD) after preoperative chemoradiotherapy among those who underwent preplanned esophagectomy;(5 years from the enrollment of the last patient)
- Comparison of PFS according to metabolic response after induction chemotherapy(5 years from the enrollment of the last patient)
- Comparison of TTF according to metabolic response after induction chemotherapy(5 years from the enrollment of the last patient)
- treatment-related mortality(up to 60 days after completion of treatment)
研究者
Sung-Bae Kim
Professor
Asan Medical Center
研究点 (2)
Loading locations...
相似试验
已完成
3 期
Multi-Center Prospective Randomized Trial Comparing Standard Esophagectomy Against Chemo-Radiotherapy for Treatment of Squamous Esophageal Cancer - Early Results From the Chinese University Research Group for Esophageal Cancer (CURE)Esophageal CancerNCT00165061Chinese University of Hong Kong80
已完成
2 期
Preoperative Chemoradiotherapy and MK-3475 for Esophageal Squamous Cell Carcinoma (ACTS-29)Esophageal Squamous Cell CarcinomaNCT02844075Yonsei University28
Unknown
2 期
Preoperative Concurrent Chemoradiotherapy for Locally Advanced Gastroesophageal Junction or Upper Gastric AdenocarcinomaGastroesophageal Junction AdenocarcinomaNCT02193594Peking University214
已完成
2 期
Chemoradiation and Tetrathiomolybdate (TM) in Patients With Esophageal CarcinomaEsophageal CarcinomaNCT00176800University of Michigan Rogel Cancer Center69
已完成
2 期
eoadjuvant chemoradiotherapy followed by esophagectomy for REG I positive T4, N4 or many thoracic esophageal cancerthoracic esophageal cancerJPRN-UMIN000001626The Cancer Board of Esophageal Cancer in Akita University Hospital30